Clinical Trial Update: Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating carrelizumab in combination with chemotherapy and apatinib as neoadjuvant treatment for resectable esophageal squamous cell carc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Carrelizumab (camrelizumab)
• Chemotherapy (neoadjuvant)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy | Phase 2 | Status: ACTIVE_NOT_RECRUITING